Aclarion Inc. (ACON)
9.82
1.49 (17.89%)
At close: Apr 14, 2025, 3:59 PM
10.00
1.83%
Pre-market: Apr 15, 2025, 04:48 AM EDT
Company Description
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States.
It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software.
The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021.
Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Aclarion Inc.
| Country | United States |
| IPO Date | Apr 22, 2022 |
| Industry | Medical - Healthcare Information Services |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Brent Ness |
Contact Details
Address: 951 Mariners Island Boulevard San Mateo, California United States | |
| Website | https://www.aclarion.com |
Stock Details
| Ticker Symbol | ACON |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001450501 |
| CUSIP Number | 655187409 |
| ISIN Number | US6551872012 |
| Employer ID | 00-0000000 |
| SIC Code |
Key Executives
| Name | Position |
|---|---|
| Brent Ness | Chief Executive Officer, President & Director |
| John Lorbiecki | Chief Financial Officer |
| Dr. Jeffrey John Thramann M.D. | Executive Chairman |
| Ryan Bond | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 09, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | NT 10-K | Filing |
| Mar 31, 2025 | 40-17G | Filing |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 14, 2025 | 497K | Filing |
| Mar 14, 2025 | 497 | Filing |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 06, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 28, 2025 | DEFA14A | Filing |